Figure 3.
Kaplan-Meier plots depicting recurrence in the Roswell Park Cancer Institute validation 'triple-negative' cohort. Patients in this cohort were treated with (a) doxorubicin + cyclophosphamide (AC) without a taxane or (b) AC plus a taxane. Patients treated with AC plus a taxane were furthered filtered to (c) stage II or greater, (d) stage IIB or greater, or (e) stage III or greater.